In this study, some people receive bisoprolol and some do not. The course of the study follows recovery over time during the rehabilitation program, which lasts about 3 months, with later follow-up up to 1 year. During this period, general health, daily well-being, and recovery after exercise are reviewed, along with symptoms such as tiredness, mood changes, and physical recovery. The study also looks at heart-related outcomes after rehabilitation.

The purpose of this study is to see if these diabetes medications can help stabilize or reduce the buildup of plaque in the heart’s blood vessels after a heart attack in people with diabetes. During the study, participants will take one of these medications for 12 months. The study will use a special imaging test called coronary CT angiography, which is a type of scan that takes detailed pictures of the blood vessels in the heart. This scan will be done at the beginning of the study and again after 12 months to measure any changes in the amount of plaque in the blood vessels. The main focus will be on blood vessels that were not treated during the procedure to open blocked arteries, which is called PCI or percutaneous coronary intervention.

Throughout the study, doctors will also look at other health markers including substances in the blood that show inflammation, markers that indicate how well blood sugar is controlled, and features of the plaque that might indicate higher risk. They will also check how well any treated blood vessels are healing and whether participants are taking their medication as prescribed. The study will last for approximately 12 months of treatment for each participant.

The study investigates how ranolazine works to block certain electrical currents in heart cells (specifically, the late sodium current) that can contribute to heart damage after a heart attack. Participants in the study will receive either the study medication or standard treatment. The medication will be given to patients after they have undergone an emergency procedure to open their blocked heart vessel.

During the study, which lasts up to 42 days, patients will take the medication daily. The maximum daily dose will be 1500 mg. Various tests will be performed to measure how well the small blood vessels in the heart are functioning, including special imaging of the heart. Patients will also complete questionnaires about their symptoms and quality of life.

Participants in the study may receive adenosine, tirofiban, or a placebo. These substances are administered through a process called intracoronary infusion, which means the medicine is delivered directly into the heart’s arteries using a specialized catheter. The study involves comparing the effects of these treatments against a control group to see how they influence heart recovery.

During the course of the study, the left ventricular ejection fraction, which is a measurement of how well the heart pumps blood out to the body, will be monitored. Changes in how the heart muscle moves and functions will be observed over a period of several months to assess the impact of the treatments on the heart’s ability to recover after the initial injury.

During the study, patients will receive one of the two pain medications when emergency medical services arrive to help them. The medication will be given to patients who have moderate to severe chest pain. Throughout the treatment, medical staff will measure how much the pain decreases and how quickly the pain relief occurs. They will use a pain scale where patients rate their pain from zero to ten, with higher numbers meaning more pain. The goal is to bring the pain level down to three or below.

The medical team will also monitor several other aspects during and after treatment. They will check how long it takes for the pain to reduce by half and how long it takes to reach low pain levels. They will measure heart rate, blood pressure, oxygen levels in the blood, and heart electrical activity when patients arrive at the hospital. The study will also track any unwanted effects from the medications, such as slow breathing, excessive sleepiness or agitation, dizziness, itching, nausea, vomiting, or headache. Each patient will receive treatment for one day as part of their emergency care.

People who join this study will have recently been hospitalized for a heart attack and will have had a procedure to look at the blood vessels in their heart. They will also have at least one additional risk factor, such as a previous heart attack, diabetes requiring medication, reduced kidney function, previous stroke, disease in the neck or leg arteries, or blockages in multiple heart arteries. The study medication will be started as soon as possible after the heart procedure, within a specific time window depending on the type of heart attack. Treatment will continue for up to 22 months, with monthly injections given under the skin.

During the study, doctors will monitor participants for major heart-related events including death from heart problems, another heart attack, or stroke. The study will also look at other outcomes such as the need for procedures to open blocked heart arteries, hospitalizations for heart failure, which is when the heart cannot pump blood well enough, and overall survival. The goal is to determine whether ziltivekimab can help prevent these serious complications in people who have experienced a heart attack and are at higher risk for future heart problems.

The study will use two different antibiotics: ceftriaxone, which is given through an intravenous infusion (through a vein), and amoxicillin, which is taken as tablets by mouth. These medications will target specific bacteria that have been found in the fatty deposits that build up in the arteries of patients with heart attacks.

During the study, patients will receive antibiotic treatment for up to two weeks. The medications will be used to target bacteria that are commonly found in complicated artery blockages. Patients will be monitored for heart-related events and complications over several years after receiving the treatment.

The purpose of this research is to determine if ziltivekimab is better than placebo at reducing the buildup of fatty deposits (called atherosclerosis) in the coronary arteries, which are the blood vessels that supply the heart muscle. The study will last for 12 months, during which participants will receive either ziltivekimab or placebo injections.

During the study, doctors will use special imaging techniques to look at the blood vessels of the heart to measure changes in the fatty deposits. They will also collect blood samples to measure various substances that can indicate inflammation and heart health. The study will track participants’ health outcomes, including any heart-related events that may occur during the study period.

The study aims to determine whether early treatment with dapagliflozin can provide heart protection and is safe to use in patients who have recently had a heart attack. Researchers will monitor patients for various heart-related complications, including worsening of heart failure, subsequent heart attacks, stroke, or the need for additional heart procedures.

Participants will receive either dapagliflozin or placebo for 3 months. During this time, they will undergo several tests, including cardiac MRI (a detailed heart imaging test) to measure the extent of heart damage. The study will also track other important factors such as changes in body weight, blood pressure, and various blood tests to assess heart and kidney function.

The purpose of the study is to determine if methoxyflurane, when self-administered by patients, can effectively relieve chest pain associated with a heart attack. Participants in the study will receive either methoxyflurane or morphine to manage their pain. The study will monitor how quickly and effectively each medication relieves pain and will also assess the impact on the cardiovascular system, including heart rate and blood pressure, as well as any side effects such as dizziness, nausea, or respiratory issues.

The trial will take place in a pre-hospital setting, meaning it will be conducted before patients reach the hospital. The study aims to provide valuable information on whether methoxyflurane can be a viable alternative to morphine for pain management in heart attack patients, potentially offering a more comfortable experience with fewer side effects. The trial is expected to run until 2028, with recruitment starting in 2025.

The purpose of the study is to evaluate how well these treatments work in preventing serious heart-related events, such as heart attacks, strokes, and heart failure. Participants in the study will be randomly assigned to receive either the intensified treatment or the standard treatment. The study will monitor the time it takes for participants to experience any major heart-related events, such as cardiovascular death, non-fatal heart attacks, or hospitalizations due to heart issues.

The trial is expected to run for several years, with the goal of gathering enough data to determine the effectiveness of the intensified treatment approach. By participating in this study, researchers hope to find better ways to manage heart health and prevent future heart-related problems in individuals who have already experienced a heart attack.

The purpose of the study is to assess the effectiveness of this modified anti-platelet therapy in patients who have undergone a procedure called complete revascularization. This procedure involves treating not only the blockage that caused the heart attack but also any other significant blockages in the heart’s blood vessels. The study will also involve the use of a Firehawk drug-eluting stent, a small tube inserted into the blood vessels to keep them open, which is coated with a low dose of a drug called rapamycin to help prevent further blockages.

Participants in the study will receive one of the anti-platelet medications or a placebo and will be monitored over a period of time to evaluate the occurrence of any adverse events, such as heart-related complications or bleeding. The study will last for up to 52 weeks, during which the safety and effectiveness of the treatment will be closely observed. The main goal is to determine if the modified therapy is as effective as current treatments in preventing serious health events in patients who have had a heart attack.

The purpose of this study is to compare the effectiveness of aspirin alone versus the combination of aspirin and fondaparinux sodium in patients with NSTEMI. Participants in the study will be randomly assigned to one of the two treatment groups. The study will monitor the participants over a period of time to observe outcomes such as survival rates, the occurrence of new heart attacks, and other related health events. The study aims to provide insights into which treatment approach may offer better outcomes for patients with NSTEMI.

Throughout the study, participants will receive regular check-ups and monitoring to ensure their safety and to gather data on the effectiveness of the treatments. The study will also track other health indicators, such as the length of hospital stay and heart function at the time of discharge. This research is expected to contribute valuable information to the medical community about the best treatment strategies for managing NSTEMI.

The trial will involve several medications, including Warfarin, Lysine Aspirin, Clopidogrel, Acetylsalicylic Acid, Atorvastatin, Diltiazem, Bisoprolol, Acetylcholine Chloride, Glyceryl Trinitrate, and Ramipril. These medications are used for various purposes such as preventing blood clots, reducing cholesterol, and managing heart conditions. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual medications.

Participants in the study will be monitored over a period of 12 months. During this time, their angina status and quality of life will be assessed using a questionnaire. The study will also track any major cardiovascular events, such as heart attacks or strokes, and evaluate the costs associated with healthcare for MINOCA patients. Additionally, the study will investigate the use of certain biomarkers, which are substances in the blood that can help diagnose and understand the causes of MINOCA, as well as the use of Cardiac Magnetic Resonance Imaging (CMR) to evaluate the condition. The goal is to gather information that could lead to better treatment strategies for people with MINOCA.

Participants in the study will receive either an early or delayed dose of ticagrelor while they are also receiving cangrelor. The study will compare the effects of these two timing strategies on the patients’ platelet activity. The researchers will also monitor for any major heart-related events, such as additional heart attacks or the need for further heart procedures, as well as any bleeding events, over a period of 30 days.

This study aims to improve the treatment approach for patients undergoing a procedure called , which is used to open blocked heart arteries during a STEMI. By understanding the best timing for administering ticagrelor, the study hopes to enhance patient outcomes and reduce complications associated with heart attacks.

Participants in the study will undergo the PCI procedure, which helps open blocked blood vessels in the heart. After the procedure, they will be assigned to one of the two treatment groups. The study will monitor the occurrence of any heart-related events and the extent of bleeding within the heart muscle, known as intramyocardial hemorrhage (IMH), during the first week after the procedure. The trial will last for 12 months, during which the safety and effectiveness of the treatments will be assessed.

The study will also look at other factors, such as the risk of bleeding, overall survival, and how the medications affect blood clotting and inflammation in the body. By comparing these two treatment approaches, the trial aims to provide valuable information on the best way to manage patients who have experienced a STEMI. The findings could help improve treatment strategies and outcomes for individuals with this serious heart condition.

Participants in the study will be randomly assigned to receive either apixaban or warfarin. The study will last for about three months, during which time the participants will take their assigned medication. The progress of the blood clot resolution will be monitored using a test called a transthoracic echocardiogram (TTE), which is a type of ultrasound that looks at the heart. If the TTE does not provide clear results, other imaging tests like magnetic resonance imaging (MRI) or computed tomography (CT) may be used.

Throughout the study, researchers will also keep track of any bleeding events, as both medications can increase the risk of bleeding. They will look at different types of bleeding, such as bleeding in the brain or gastrointestinal bleeding, and will also monitor for any major heart-related events. The study aims to provide valuable information on the best treatment option for patients with blood clots in the heart following a heart attack.

The purpose of the study is to determine how well this combination of medications works in lowering LDL-cholesterol levels in patients who have not achieved their cholesterol goals with the usual treatment of atorvastatin and ezetimibe alone. The study will last for a total of 8 weeks, during which patients will take the triple therapy of atorvastatin, ezetimibe, and bempedoic acid. The effectiveness of this treatment will be assessed by measuring the proportion of patients who reach the target cholesterol levels after the treatment period.

Participants in the study will be monitored for changes in their cholesterol levels, as well as other health indicators such as total cholesterol, HDL-cholesterol (often called “good cholesterol”), triglycerides, and blood pressure. The study will also look at the overall quality of life of the participants during the treatment period. This research aims to provide valuable information on whether adding bempedoic acid to the existing treatment can help patients better manage their cholesterol levels after a heart attack.

Participants in the study will be randomly assigned to receive either Selatogrel or a Selatogrel matching placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are unbiased. The study will follow participants over a period to observe the occurrence of death or another heart attack after they have self-administered the treatment.

The study will also monitor for any safety concerns, such as bleeding events, that may occur within two days after taking the treatment. Additionally, researchers will look at other outcomes like hospital visits for heart failure within 30 days after treatment. This trial aims to provide valuable information on the potential benefits and risks of using Selatogrel for individuals at risk of having another heart attack.

The research examines the use of noradrenaline, a medication given through an intravenous infusion to raise blood pressure in patients with cardiogenic shock. The study aims to determine if using lower doses of noradrenaline to maintain a lower blood pressure target leads to better outcomes compared to standard treatment.

During the study, participants will be divided into two groups. One group will receive the standard blood pressure treatment, while the other group will receive treatment aimed at maintaining a lower blood pressure target with reduced noradrenaline use. The study will track the survival of patients and their kidney function over a 30-day period after treatment begins.

Participants in the study will receive either the RTP-026 treatment or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are unbiased. The study will take place over a period of time, with multiple doses being administered to evaluate how well the treatment works and how safe it is for the patients.

Throughout the study, various health checks will be conducted, including monitoring vital signs, performing ECGs (electrocardiograms), and taking blood samples to measure specific markers related to heart health. The study aims to gather information on how RTP-026 affects the heart and overall recovery after a STEMI, with the goal of improving treatment options for this serious condition.

The purpose of the study is to estimate how many patients experience the resolution of the blood clot in the heart and whether they have any new brain infarctions, which are areas of dead tissue due to lack of blood supply, after three months of treatment. The study will compare the effects of dabigatran etexilate and phenprocoumon over a period of three months. Some participants will receive a placebo, which is a substance with no active medication, to help compare the effects of the actual medications.

Participants in the study will take the medication or placebo for up to three months. During this time, they will be monitored for any changes in their condition, including the resolution of the blood clot and any new brain infarctions. The study will also track any bleeding events that occur during the treatment period and for up to one year afterward. This information will help researchers understand the effectiveness and safety of these treatments for patients with left ventricular thrombosis after a STEMI.

Participants in the study will take Brilique 90 mg film-coated tablets, which contain ticagrelor, for a period of time. The study will monitor the participants for any serious heart-related events, such as cardiac death, another heart attack, or issues with the stent, within the first three months. Additionally, the study will observe the occurrence of bleeding events and other health outcomes over a period of up to 12 months.

The study aims to gather information on how safe it is to use ticagrelor as a single treatment after a heart attack and stenting. This will help doctors understand if this approach can be a reliable option for patients in the future. Participants will be closely monitored throughout the study to ensure their safety and to collect valuable data on the effects of the medication.

Participants in the study will receive either the medications or a placebo. The study will monitor changes in heart function using a test called echocardiography, which uses sound waves to create images of the heart. The study will also measure specific blood markers that indicate heart health. These assessments will help determine the impact of the medications on heart recovery after a heart attack.

The study will take place over a period of time, with participants being monitored at various intervals. The main focus will be on heart function and recovery within the first week after treatment, with additional follow-ups to assess longer-term effects. This research aims to provide valuable insights into the best timing and combination of these medications for improving outcomes in patients with STEMI.

The purpose of the study is to assess the safety of ApTOLL at two different doses in patients who are candidates for emergency procedures to open blocked heart arteries, known as angioplasty, without having received clot-dissolving medications. Participants in the study will receive ApTOLL through an intravenous bolus, which means it is given directly into a vein in a single, quick dose. The study will monitor participants for any adverse effects, such as severe low blood pressure, irregular heart rhythms, or heart failure, over a period of 90 days after receiving the treatment.

Throughout the study, the effects of ApTOLL on the heart will be measured using imaging techniques like MRI and echocardiography. These tests will help determine changes in the size of the heart attack area and the heart’s ability to pump blood. Additionally, the study will measure levels of certain proteins in the blood that indicate inflammation and heart damage. These measurements will be taken at various times after the treatment to understand how ApTOLL affects the heart and the body’s response to the heart attack.

The purpose of the study is to see if BI 765845 can help improve the condition of patients who have had a heart attack when used alongside the standard care they are already receiving. The trial will also explore the best dose of BI 765845 to use in future studies. Participants in the study will receive either BI 765845 or a placebo, and their progress will be monitored to assess the treatment’s impact on their recovery.

During the study, participants will receive a single administration of the treatment and will be closely observed to ensure their safety and to gather information on how well the treatment works. The study aims to identify the most effective dose of BI 765845 for use in further research. This trial is an important step in developing new treatments for heart attack patients and could lead to improved outcomes for those affected by this condition.

The purpose of the study is to see if Colchicine can improve blood flow in the heart and reduce symptoms in patients with CMD. The study will last for about six months. During this time, participants will undergo various assessments, including heart scans, to measure changes in blood flow and symptom questionnaires to evaluate any changes in their angina symptoms. The study will also look at how Colchicine affects certain proteins and functions in the blood vessels.

In addition to Colchicine, the study will involve the use of Regadenoson and Adenosine, which are substances used to stress the heart during certain tests, and local anesthetics, which are used to numb specific areas of the body. These substances will help researchers better understand the effects of Colchicine on heart function and blood flow. The study aims to provide valuable insights into potential new treatments for CMD and improve the quality of life for those affected by this condition.

The purpose of the study is to assess the outcomes of patients 30 days after receiving the treatment. Participants will receive a single injection of Zalunfiban or a placebo before they reach the hospital. The study will monitor the patients for any major health events, such as death, stroke, or another heart attack, as well as any bleeding incidents, which are important safety concerns. The study aims to provide insights into how Zalunfiban might help improve the condition of patients with STEMI when administered early.

Throughout the study, patients will be observed for any side effects or reactions at the injection site. The trial will also track the patients’ recovery and any additional treatments they might need. This research is important for understanding how Zalunfiban can be used to potentially improve outcomes for people experiencing a heart attack, offering new possibilities for treatment in emergency situations.

Participants in the study will be randomly assigned to receive either evolocumab or the usual care strategies. The study will follow participants for up to 36 months, with regular check-ups to monitor cholesterol levels and other health indicators. These check-ups will occur at various intervals, including 6 weeks, 22 weeks, and 12 months after starting the treatment, and may continue up to 24 months or longer, depending on the availability of data. The study will also look at how quickly participants can reach their target cholesterol levels and any changes in other types of cholesterol and fats in the blood.

The purpose of this study is to determine if evolocumab is more effective than standard treatments in helping patients who have had a heart attack achieve healthier cholesterol levels, which could potentially reduce the risk of future heart-related problems. By participating in this study, researchers hope to gather valuable information that could improve treatment strategies for managing cholesterol levels in patients with heart disease.